Long Term Follow-Up of Subjects Exposed to GSK3377794

This is a non-therapeutic, multi-center, LTFU study of subjects who have, in a previous
GlaxoSmithKline (GSK) clinical trial, received GSK3377794 (NY-ESO-1ᶜ²⁵⁹T) by a process that
utilizes lentiviral vectors. This protocol is designed in adherence with Food and Drug
Administration (FDA) and European Medicines Agency (EMA) guidelines. The study involves up to
15 years post-infusion monitoring of subjects who have been exposed to lentivirus-mediated
gene transfer in GSK clinical studies. Subjects will undergo clinical evaluation (i.e., new
medical history, physical exam, adverse events, and exposure to mutagenic agents, anti-cancer
therapies and investigational products in other clinical studies) with careful attention to
adverse events possibly related to gene transfer or lentivirus-induced diseases. Blood
samples will be collected for evaluating persistence of cells with lentiviral vector
sequences, the detection of replication competent lentivirus (RCL), and chemistry and
hematology laboratory assessments. Subjects will be followed for survival.

Inclusion Criteria:

- Subjects who have received at least one dose of GSK3377794 in the interventional
study.

- Subjects who have either completed the interventional study or have withdrawn from it.

- Male or Female subjects.

- Capable of giving signed informed consent prior to the study participation.

Exclusion Criteria: